Trial · NCT03520842
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression Free Survival (PFS) | Treatment (Regorafenib, Methotrexate) | 3.7 | 95% Confidence Interval 1.8 to 8.6 | months | |
| Objective Response Rate (ORR) | Treatment (Regorafenib, Methotrexate) | 16.7 | 95% Confidence Interval 3.5 to 41.4 | percentage of participants | |
| Disease Control Rate (DCR) | Treatment (Regorafenib, Methotrexate) | 66.7 | 95% Confidence Interval 41.0 to 86.7 | percentage of participants | |
| Number of Participants With Adverse Events | Treatment (Regorafenib, Methotrexate) | Any grade | 17 | Participants | |
| Number of Participants With Adverse Events | Treatment (Regorafenib, Methotrexate) | ≥ grade 3 | 14 | Participants | |
| Trough Serum Concentration of Methotrexate | Treatment (Regorafenib, Methotrexate) | Cycle 1, Day 1 | 0.04 | Standard Deviation 0.02 | μmol/L |
| Trough Serum Concentration of Methotrexate | Treatment (Regorafenib, Methotrexate) | Cycle 1, Day 8 | 0.04 | Standard Deviation 0.01 | μmol/L |
| Trough Serum Concentration of Methotrexate | Treatment (Regorafenib, Methotrexate) | Cycle 1, Day 15 | 0.05 | Standard Deviation 0.03 | μmol/L |
| Trough Serum Concentration of Methotrexate | Treatment (Regorafenib, Methotrexate) | Cycle 1, Day 22 | 0.05 | Standard Deviation 0.02 | μmol/L |
| Maximum Serum Concentration (Cmax) of Methotrexate | Treatment (Regorafenib, Methotrexate) | Cycle 1, Day 1 | 0.43 | Standard Deviation 0.23 | μmol/L |
| Maximum Serum Concentration (Cmax) of Methotrexate | Treatment (Regorafenib, Methotrexate) | Cycle 1, Day 8 | 0.60 | Standard Deviation 0.30 | μmol/L |
| Maximum Serum Concentration (Cmax) of Methotrexate | Treatment (Regorafenib, Methotrexate) | Cycle 1, Day 15 | 0.60 | Standard Deviation 0.43 | μmol/L |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03520842/results